PDF(Pubmed)
Abstract：
UNASSIGNED: Myocarditis has been reported following the first two doses of Pfizer-BNT162b2 messenger RNA (mRNA) COVID-19 vaccination. Administration of a third dose (booster) of the vaccine was initiated recently in Israel.
UNASSIGNED: The aim of this study was to describe the characteristics of patients referred for cardiac magnetic resonance (CMR) imaging with myocarditis following the booster.
UNASSIGNED: Patients referred for CMR imaging with a clinical diagnosis of myocarditis within 21 days following the booster, between July 13 and November 11, 2021, were analyzed.
UNASSIGNED: Overall, 4 patients were included, 3/4 (75%) were men, and the mean age was 27 ± 10 years. The time from booster administration to the onset of symptoms was 5.75 ± 4.8 days (range 2-14). Obstructive coronary artery disease was excluded in 3 of the patients (75%). CMR was performed 34 ± 15 days (range 8-47 days) following the 3rd vaccination. The mean left ventricular ejection fraction was 61 ± 7% (range 53-71%), and regional wall motion abnormalities were present in one of the patients. Global T1 was increased in one of the patients, while focal T1 values were increased in 3 of the patients. Global T2 was increased in one of the patients, while focal T2 values were increased in all the patients. Global ECV was increased in 3 of the patients, while focal ECV was increased in all the patients. Median late gadolinium enhancement (LGE) was 4 ± 3% (range 1-9%), with the inferolateral segment as the most common location (3 of the 4 patients). All the patients met the Updated Lake Louise Criteria.
UNASSIGNED: Patient characteristics and CMR imaging findings of myocarditis following the administration of the booster vaccine are relatively mild and consistent with those observed with the first two doses. Although larger-scale prospective studies are necessary, these initial findings are somewhat reassuring.
UNASSIGNED: The aim of this study was to describe the characteristics of patients referred for cardiac magnetic resonance (CMR) imaging with myocarditis following the booster.
UNASSIGNED: Patients referred for CMR imaging with a clinical diagnosis of myocarditis within 21 days following the booster, between July 13 and November 11, 2021, were analyzed.
UNASSIGNED: Overall, 4 patients were included, 3/4 (75%) were men, and the mean age was 27 ± 10 years. The time from booster administration to the onset of symptoms was 5.75 ± 4.8 days (range 2-14). Obstructive coronary artery disease was excluded in 3 of the patients (75%). CMR was performed 34 ± 15 days (range 8-47 days) following the 3rd vaccination. The mean left ventricular ejection fraction was 61 ± 7% (range 53-71%), and regional wall motion abnormalities were present in one of the patients. Global T1 was increased in one of the patients, while focal T1 values were increased in 3 of the patients. Global T2 was increased in one of the patients, while focal T2 values were increased in all the patients. Global ECV was increased in 3 of the patients, while focal ECV was increased in all the patients. Median late gadolinium enhancement (LGE) was 4 ± 3% (range 1-9%), with the inferolateral segment as the most common location (3 of the 4 patients). All the patients met the Updated Lake Louise Criteria.
UNASSIGNED: Patient characteristics and CMR imaging findings of myocarditis following the administration of the booster vaccine are relatively mild and consistent with those observed with the first two doses. Although larger-scale prospective studies are necessary, these initial findings are somewhat reassuring.
摘要：
未经证实：在前两剂辉瑞-BNT162b2信使RNA（mRNA）COVID-19疫苗接种后，已报道心肌炎。最近在以色列开始施用第三剂疫苗(加强剂)。
UNASSIGNED：这项研究的目的是描述在加强后进行心脏磁共振（CMR）成像的心肌炎患者的特征。
未经证实：在加强治疗后21天内，临床诊断为心肌炎的CMR成像患者，2021年7月13日至11月11日，进行了分析。
未经评估：总的来说，包括4名患者，3/4（75%）是男性，平均年龄为27±10岁。从加强给药到症状发作的时间为5.75±4.8天（范围2-14）。3名患者（75％）排除了阻塞性冠状动脉疾病。在第三次接种后34±15天(范围8-47天)进行CMR。平均左心室射血分数为61±7%（范围53-71%），其中一名患者存在局部室壁运动异常。其中一名患者的全球T1升高，而3例患者的局灶性T1值增加。其中一名患者的全局T2升高，而所有患者的局灶性T2值均增加。3名患者的全球ECV增加，而所有患者的局灶性ECV均增加。中位晚钆增强(LGE)为4±3%(范围1-9%)，以下外侧段为最常见的位置（4例患者中的3例）。所有患者均符合LouiseLake更新标准。
未经证实：给予加强疫苗后心肌炎的患者特征和CMR影像学表现相对温和，与前两剂观察到的一致。虽然大规模的前瞻性研究是必要的，这些初步发现有些令人放心。
UNASSIGNED：这项研究的目的是描述在加强后进行心脏磁共振（CMR）成像的心肌炎患者的特征。
未经证实：在加强治疗后21天内，临床诊断为心肌炎的CMR成像患者，2021年7月13日至11月11日，进行了分析。
未经评估：总的来说，包括4名患者，3/4（75%）是男性，平均年龄为27±10岁。从加强给药到症状发作的时间为5.75±4.8天（范围2-14）。3名患者（75％）排除了阻塞性冠状动脉疾病。在第三次接种后34±15天(范围8-47天)进行CMR。平均左心室射血分数为61±7%（范围53-71%），其中一名患者存在局部室壁运动异常。其中一名患者的全球T1升高，而3例患者的局灶性T1值增加。其中一名患者的全局T2升高，而所有患者的局灶性T2值均增加。3名患者的全球ECV增加，而所有患者的局灶性ECV均增加。中位晚钆增强(LGE)为4±3%(范围1-9%)，以下外侧段为最常见的位置（4例患者中的3例）。所有患者均符合LouiseLake更新标准。
未经证实：给予加强疫苗后心肌炎的患者特征和CMR影像学表现相对温和，与前两剂观察到的一致。虽然大规模的前瞻性研究是必要的，这些初步发现有些令人放心。
